News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AstraZeneca PLC (AZN) Steps Up Push Into Cancer Immunotherapy, Falls Behind Rivals Such As Bristol-Myers Squibb Company (BMY), Merck & Co., Inc. (MRK), And Roche (RHHBY)


7/31/2014 7:47:00 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

(Reuters) - AstraZeneca is accelerating its push into cancer immunotherapy, with plans to test a key experimental drug in new tumor types.

The company is seen as No. 4 in a race to develop the first drug in a new class that fights cancer by unleashing the body's immune system, behind rivals Roche, Merck & Co and Bristol-Myers Squibb.

But its MEDI4736 medicine is still viewed as a highly promising agent, both on its own and in combination with other treatments.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters


comments powered by Disqus
Reuters
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES